VNDA
Vanda Pharmaceuticals Inc
4.60$
-3.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 7.9% | 7.6% | 11.5% | 8.9% | 5.4% | 4.9% | 7.0% | 8.5% | 5.3% | 6.7% | 10.0% | 7.0% | 7.2% | |
| 92.1% | 92.4% | 88.5% | 91.1% | 94.6% | 95.1% | 93.0% | 91.5% | 94.7% | 93.3% | 90.0% | 93.0% | 92.8% | |
| 42.8% | 53.8% | 44.6% | 33.0% | 35.2% | 37.3% | 71.4% | 41.8% | 40.1% | 50.7% | 55.0% | 73.1% | 54.2% | |
| 63.8% | 51.1% | 63.4% | 78.2% | 78.9% | 70.3% | 100.1% | 122.9% | 107.1% | 110.1% | 132.2% | 142.2% | 122.1% | |
| 107.6% | 108.0% | 108.0% | 111.2% | 117.7% | 114.5% | 182.0% | 164.7% | 150.4% | 163.8% | 187.2% | 219.2% | 178.9% | |
| -15.4% | -15.7% | -19.5% | -20.1% | -23.1% | -19.3% | -89.0% | -73.2% | -55.6% | -70.5% | -97.1% | -126.3% | -86.1% | |
| – | 7.8% | – | – | – | – | – | – | – | – | – | – | – | |
| -0.3% | -3.7% | -9.8% | -10.9% | -13.1% | -12.2% | -74.7% | -66.3% | -50.5% | -66.4% | -93.6% | -123.5% | -82.1% | |
| -0.7% | 1.6% | -1.1% | -2.0% | -1.9% | -3.0% | -15.7% | -14.6% | -10.3% | 180.3% | 0.3% | 0.3% | 45.3% | |
| 0.4% | -5.3% | -8.7% | -9.0% | -11.2% | -9.2% | -58.9% | -51.7% | -40.1% | -246.8% | -93.9% | -123.7% | -127.4% | |
| 1.2% | -1.1% | -5.1% | -7.0% | -9.0% | -8.5% | -62.2% | -62.5% | -46.8% | -56.2% | -86.8% | -125.2% | -77.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.